BioVentrix Announces NUB Reimbursement Status 1 for Revivent TC™ TransCatheter Ventricular Enhancement System in Germany

6 February 2017

BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), announced that InEk, the German Institute for the Hospital Remuneration System, has awarded NUB Status 1 for the Revivent TC™ TransCatheter Ventricular Enhancement System. The NUB process supports introduction of new and innovative medical devices in Germany. It allows[…]

Boston Scientific Closes Acquisition of Neovasc Advanced Biological Tissue Capabilities, Acquires 15% Stake

2 January 2017

With the completion of the acquisition, Boston Scientific will integrate certain manufacturing assets and biologic tissue capabilities into its structural heart business for use in the manufacturing of the Lotus™ Valve System* and future heart valve technologies. The two organizations announced a definitive agreement for Boston Scientific to acquire the advanced biologic tissue capabilities and[…]

RENASCENT-III Trial investigates 100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold

30 November 2016

Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation MAGNITUDE™ sirolimus-eluting bioresorbable scaffold (BRS) scaffold, which has a strut thickness in the sub-100-micron range. Dr. Antonio Colombo, director of the Hemodynamics Division at Ospedale San Raffaele in Milan, Italy and Dr. Juan F. Granada, executive[…]

FASTRIAL goes worldwide !

Meditrial has released a new version of its successful EDC builder. FASTRIAL is now hosted on the Google cloud. Installed on Google servers in Europe, USA and ASIA, it offers the most secured environment to all your critical data. In addition the connection speed to your study is now unbelievable. You will be directed to the closest[…]